menu
    • menu
    [{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Suzhou Royaltech Med Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"MV-based mRNA Therapeutic","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Suzhou Royaltech Med Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Porton Advanced Solutions \/ Suzhou Royaltech Med Co., Ltd."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Bennu Biotherapeutics"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Bennu Biotherapeutics"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine Inc","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine Inc"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Ascle Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Ascle Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Ascle Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Porton Advanced Solutions

    Menu

    Porton Advanced Solutions

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ascle Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells ...

                            Details : According to the agreement, Porton Advanced will provide services of development, and production in China with Ascle Therapeutics' NK cell project, supporting the application of NK cells in cancer prevention, anti-aging.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ascle Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRL-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : BRL Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell ...

                            Details : The partnership will enhance the cell and gene therapy pipelines, including BRL-101, which was developed using the in-house ModiHSC® hematopoietic stem cell platform, from BRL Medicine from clinical trials to further expedite the commercialization of in...

                            Brand Name : BRL-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2023

                            Lead Product(s) : BRL-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : BRL Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bennu Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Develop...

                            Details : The partnership aims to accelerate the development of T-cell therapies for tumors and autoimmune diseases. Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg, to Be...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bennu Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bennu Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Engineering Dev...

                            Details : Through the partnership, Porton will assist Bennu in accelerating and focusing on the development of T-cell therapies for the treatment of solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bennu Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRL-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : BRL Medicine Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of CGT

                            Details : Through the partnership, Porton will assist BRL Medicine's lead candidate BRL-101, which is a BCL11A gene inhibitor. It is being evaluated in the clinical trial studies for the treatment of Beta-Thalassemia and Sickle Cell Disease.

                            Brand Name : BRL-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 03, 2023

                            Lead Product(s) : BRL-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : BRL Medicine Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

                            Details : Under the terms of the collaboration, Porton Advanced Solutions and DanausGT Biotechnology will expedite the development of innovative therapeutics in gene and cell therapy pipelines.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Engineering

                            Details : This collaboration will accelerate the development of innovative therapeutics for the treatment of some diseases such as blood, skin, and liver-related diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MV-based mRNA Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Suzhou Royaltech Med Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Porton Advanced and Royaltech Announce Strategic Collaboration to Accelerate the Development of Bacterial Drug...

                            Details : The strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy and mRNA drug platform technology, and accelerate the R&D process of bioinnova...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 29, 2022

                            Lead Product(s) : MV-based mRNA Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Suzhou Royaltech Med Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth